

Global GLP-1/GIPR Dual Peptide Agonist Supply, Demand and Key Producers, 2026-2032

<https://marketpublishers.com/r/GE3890F720D6EN.html>

Date: February 2026

Pages: 97

Price: US\$ 4,480.00 (Single User License)

ID: GE3890F720D6EN

Abstracts

The global GLP-1/GIPR Dual Peptide Agonist market size is expected to reach \$ 65293 million by 2032, rising at a market growth of 11.0% CAGR during the forecast period (2026-2032).

In 2025, global GLP-1/GIPR Dual Peptide Agonist production reached approximately 156.36 M Units, with an average global market price of around 193.26 USD per Unit.

A GLP-1/GIPR Dual Peptide Agonist is a single therapeutic agent (usually a peptide) designed to activate both the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR). By stimulating these two incretin pathways together, it aims to improve metabolic control—typically by enhancing glucose-dependent insulin secretion, reducing glucagon when appropriate, slowing gastric emptying, and decreasing appetite/food intake—so it can support blood-glucose lowering and weight loss in conditions such as type 2 diabetes and obesity. To date, Tirzepatide is the only commercially available GLP-1/GIPR Dual Peptide Agonist product in the world.

GLP-1/GIPR Dual Peptide Agonists are reshaping the incretin field because they tackle a long-standing clinical and commercial pain point in metabolic care: achieving meaningful, sustained weight reduction and cardiometabolic improvement without forcing patients and providers into a tradeoff between efficacy, tolerability, and long-term adherence. By co-activating GLP-1 and GIP pathways in a single molecule, these therapies can deliver a broader metabolic effect than GLP-1 alone—supporting glucose control while driving appetite reduction and weight loss that can translate into improvements across obesity-linked comorbidities—while modern long-acting designs and carefully tuned receptor balance aim to preserve potency with manageable gastrointestinal burden and simpler dosing routines. Industry momentum is being driven

by unprecedented demand for effective obesity and diabetes treatments, rising recognition of obesity as a chronic disease with downstream health-system costs, strong payer and employer interest in outcomes that reduce long-term risk, and rapid advances in peptide engineering, formulation, and device delivery that make scalable, patient-friendly products feasible. The market potential remains substantial as dual agonists expand from specialist-driven use toward broader chronic-care adoption, diversify into new formulations and delivery formats, and compete through differentiation on tolerability, durability of effect, and real-world outcomes, positioning the category as a durable growth engine within biopharma's most strategically important therapeutic area.

The upstream raw materials for GLP-1/GIPR Dual Peptide Agonist mainly include amino acids, condensation reagents, activators, resin carriers, etc. Typical raw material suppliers include Merck, Bachem, AAPPTec, Thermo Fisher, etc. The downstream applications are mainly in the treatment of obesity and diabetes.

The single-line production capacity of GLP-1/GIPR Dual Peptide Agonist varies significantly depending on the drug molecule type, process complexity, equipment scale, and production mode. Industry gross margins typically range from 60% to 80%.

This report studies the global GLP-1/GIPR Dual Peptide Agonist production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for GLP-1/GIPR Dual Peptide Agonist and provides market size (US\$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of GLP-1/GIPR Dual Peptide Agonist that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global GLP-1/GIPR Dual Peptide Agonist total production and demand, 2021-2032, (K Units)

Global GLP-1/GIPR Dual Peptide Agonist total production value, 2021-2032, (USD Million)

Global GLP-1/GIPR Dual Peptide Agonist production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)

Global GLP-1/GIPR Dual Peptide Agonist consumption by region & country, CAGR, 2021-2032 & (K Units)

U.S. VS China: GLP-1/GIPR Dual Peptide Agonist domestic production, consumption,

key domestic manufacturers and share

Global GLP-1/GIPR Dual Peptide Agonist production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)

Global GLP-1/GIPR Dual Peptide Agonist production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)

Global GLP-1/GIPR Dual Peptide Agonist production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)

This report profiles key players in the global GLP-1/GIPR Dual Peptide Agonist market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eli Lilly, Roche, Viking Therapeutics, Asclepis Pharma, Jiangsu Hengrui Medicine, East China Pharmaceutical, Tonghua Dongbao Pharmaceutical, Lepu Medical Technology, Hansoh Pharma, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World GLP-1/GIPR Dual Peptide Agonist market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), volume (production, consumption) & (K Units) and average price (US\$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global GLP-1/GIPR Dual Peptide Agonist Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global GLP-1/GIPR Dual Peptide Agonist Market, Segmentation by Type:

Injection

Oral Administration

Global GLP-1/GIPR Dual Peptide Agonist Market, Segmentation by Receptor Agonist Properties:

Balanced

Biased

Global GLP-1/GIPR Dual Peptide Agonist Market, Segmentation by Medicinal Efficacy:

Long-acting

Short-acting

Global GLP-1/GIPR Dual Peptide Agonist Market, Segmentation by Application:

Diabetes

Obesity

Others

Companies Profiled:

Eli Lilly

Roche

Viking Therapeutics

Ascletis Pharma

Jiangsu Hengrui Medicine

East China Pharmaceutical

Tonghua Dongbao Pharmaceutical

Lepu Medical Technology

Hansoh Pharma

Key Questions Answered:

1. How big is the global GLP-1/GIPR Dual Peptide Agonist market?
2. What is the demand of the global GLP-1/GIPR Dual Peptide Agonist market?
3. What is the year over year growth of the global GLP-1/GIPR Dual Peptide Agonist market?
4. What is the production and production value of the global GLP-1/GIPR Dual Peptide Agonist market?
5. Who are the key producers in the global GLP-1/GIPR Dual Peptide Agonist market?
6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

- 1.1 Aerospace Testing Solutions Introduction
- 1.2 World Aerospace Testing Solutions Market Size & Forecast (2021 & 2025 & 2032)
- 1.3 World Aerospace Testing Solutions Total Market by Region (by Headquarter Location)
 - 1.3.1 World Aerospace Testing Solutions Market Size by Region (2021-2032), (by Headquarter Location)
 - 1.3.2 United States Based Company Aerospace Testing Solutions Revenue (2021-2032)
 - 1.3.3 China Based Company Aerospace Testing Solutions Revenue (2021-2032)
 - 1.3.4 Europe Based Company Aerospace Testing Solutions Revenue (2021-2032)
 - 1.3.5 Japan Based Company Aerospace Testing Solutions Revenue (2021-2032)
 - 1.3.6 South Korea Based Company Aerospace Testing Solutions Revenue (2021-2032)
 - 1.3.7 ASEAN Based Company Aerospace Testing Solutions Revenue (2021-2032)
 - 1.3.8 India Based Company Aerospace Testing Solutions Revenue (2021-2032)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 Aerospace Testing Solutions Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 Major Market Trends

2 DEMAND SUMMARY

- 2.1 World Aerospace Testing Solutions Consumption Value (2021-2032)
- 2.2 World Aerospace Testing Solutions Consumption Value by Region
 - 2.2.1 World Aerospace Testing Solutions Consumption Value by Region (2021-2026)
 - 2.2.2 World Aerospace Testing Solutions Consumption Value Forecast by Region (2027-2032)
- 2.3 United States Aerospace Testing Solutions Consumption Value (2021-2032)
- 2.4 China Aerospace Testing Solutions Consumption Value (2021-2032)
- 2.5 Europe Aerospace Testing Solutions Consumption Value (2021-2032)
- 2.6 Japan Aerospace Testing Solutions Consumption Value (2021-2032)
- 2.7 South Korea Aerospace Testing Solutions Consumption Value (2021-2032)
- 2.8 ASEAN Aerospace Testing Solutions Consumption Value (2021-2032)
- 2.9 India Aerospace Testing Solutions Consumption Value (2021-2032)

3 WORLD AEROSPACE TESTING SOLUTIONS COMPANIES COMPETITIVE ANALYSIS

- 3.1 World Aerospace Testing Solutions Revenue by Player (2021-2026)
- 3.2 Industry Rank and Concentration Rate (CR)
 - 3.2.1 Global Aerospace Testing Solutions Industry Rank of Major Players
 - 3.2.2 Global Concentration Ratios (CR4) for Aerospace Testing Solutions in 2025
 - 3.2.3 Global Concentration Ratios (CR8) for Aerospace Testing Solutions in 2025
- 3.3 Aerospace Testing Solutions Company Evaluation Quadrant
- 3.4 Aerospace Testing Solutions Market: Overall Company Footprint Analysis
 - 3.4.1 Aerospace Testing Solutions Market: Region Footprint
 - 3.4.2 Aerospace Testing Solutions Market: Company Product Type Footprint
 - 3.4.3 Aerospace Testing Solutions Market: Company Product Application Footprint
- 3.5 Competitive Environment
 - 3.5.1 Historical Structure of the Industry
 - 3.5.2 Barriers of Market Entry
 - 3.5.3 Factors of Competition
- 3.6 Mergers & Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)

- 4.1 United States VS China: Aerospace Testing Solutions Revenue Comparison (by Headquarter Location)
 - 4.1.1 United States VS China: Aerospace Testing Solutions Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
 - 4.1.2 United States VS China: Aerospace Testing Solutions Revenue Market Share Comparison (2021 & 2025 & 2032)
- 4.2 United States Based Companies VS China Based Companies: Aerospace Testing Solutions Consumption Value Comparison
 - 4.2.1 United States VS China: Aerospace Testing Solutions Consumption Value Comparison (2021 & 2025 & 2032)
 - 4.2.2 United States VS China: Aerospace Testing Solutions Consumption Value Market Share Comparison (2021 & 2025 & 2032)
- 4.3 United States Based Aerospace Testing Solutions Companies and Market Share, 2021-2026
 - 4.3.1 United States Based Aerospace Testing Solutions Companies, Headquarters (States, Country)
 - 4.3.2 United States Based Companies Aerospace Testing Solutions Revenue,

(2021-2026)

4.4 China Based Companies Aerospace Testing Solutions Revenue and Market Share, 2021-2026

4.4.1 China Based Aerospace Testing Solutions Companies, Company Headquarters (Province, Country)

4.4.2 China Based Companies Aerospace Testing Solutions Revenue, (2021-2026)

4.5 Rest of World Based Aerospace Testing Solutions Companies and Market Share, 2021-2026

4.5.1 Rest of World Based Aerospace Testing Solutions Companies, Headquarters (Province, Country)

4.5.2 Rest of World Based Companies Aerospace Testing Solutions Revenue (2021-2026)

5 MARKET ANALYSIS BY TYPE

5.1 World Aerospace Testing Solutions Market Size Overview by Type: 2021 VS 2025 VS 2032

5.2 Segment Introduction by Type

5.2.1 Mechanical Testing

5.2.2 Materials Testing

5.2.3 Environmental Testing

5.3 Market Segment by Type

5.3.1 World Aerospace Testing Solutions Market Size by Type (2021-2026)

5.3.2 World Aerospace Testing Solutions Market Size by Type (2027-2032)

5.3.3 World Aerospace Testing Solutions Market Size Market Share by Type (2027-2032)

6 MARKET ANALYSIS BY TESTING CATEGORY

6.1 World Aerospace Testing Solutions Market Size Overview by Testing Category: 2021 VS 2025 VS 2032

6.2 Segment Introduction by Testing Category

6.2.1 Component Testing

6.2.2 System Integration Testing

6.2.3 Full-Scale Vehicle Testing

6.2.4 Post-Launch & Maintenance Testing

6.3 Market Segment by Testing Category

6.3.1 World Aerospace Testing Solutions Market Size by Testing Category (2021-2026)

6.3.2 World Aerospace Testing Solutions Market Size by Testing Category (2027-2032)

6.3.3 World Aerospace Testing Solutions Market Size Market Share by Testing Category (2027-2032)

7 MARKET ANALYSIS BY APPLICATION

7.1 World Aerospace Testing Solutions Market Size Overview by Application: 2021 VS 2025 VS 2032

7.2 Segment Introduction by Application

7.2.1 Commercial

7.2.2 Military

7.3 Market Segment by Application

7.3.1 World Aerospace Testing Solutions Market Size by Application (2021-2026)

7.3.2 World Aerospace Testing Solutions Market Size by Application (2027-2032)

7.3.3 World Aerospace Testing Solutions Market Size Market Share by Application (2021-2032)

8 COMPANY PROFILES

8.1 Applied Technical Services (ATS)

8.1.1 Applied Technical Services (ATS) Details

8.1.2 Applied Technical Services (ATS) Major Business

8.1.3 Applied Technical Services (ATS) Aerospace Testing Solutions Product and Services

8.1.4 Applied Technical Services (ATS) Aerospace Testing Solutions Revenue, Gross Margin and Market Share (2021-2026)

8.1.5 Applied Technical Services (ATS) Recent Developments/Updates

8.1.6 Applied Technical Services (ATS) Competitive Strengths & Weaknesses

8.2 Element Materials Technology

8.2.1 Element Materials Technology Details

8.2.2 Element Materials Technology Major Business

8.2.3 Element Materials Technology Aerospace Testing Solutions Product and Services

8.2.4 Element Materials Technology Aerospace Testing Solutions Revenue, Gross Margin and Market Share (2021-2026)

8.2.5 Element Materials Technology Recent Developments/Updates

8.2.6 Element Materials Technology Competitive Strengths & Weaknesses

8.3 Regal Rexnord Corporation

- 8.3.1 Regal Rexnord Corporation Details
- 8.3.2 Regal Rexnord Corporation Major Business
- 8.3.3 Regal Rexnord Corporation Aerospace Testing Solutions Product and Services
- 8.3.4 Regal Rexnord Corporation Aerospace Testing Solutions Revenue, Gross Margin and Market Share (2021-2026)
- 8.3.5 Regal Rexnord Corporation Recent Developments/Updates
- 8.3.6 Regal Rexnord Corporation Competitive Strengths & Weaknesses
- 8.4 Elite Electronic Engineering
 - 8.4.1 Elite Electronic Engineering Details
 - 8.4.2 Elite Electronic Engineering Major Business
 - 8.4.3 Elite Electronic Engineering Aerospace Testing Solutions Product and Services
 - 8.4.4 Elite Electronic Engineering Aerospace Testing Solutions Revenue, Gross Margin and Market Share (2021-2026)
 - 8.4.5 Elite Electronic Engineering Recent Developments/Updates
 - 8.4.6 Elite Electronic Engineering Competitive Strengths & Weaknesses
- 8.5 Andrew Tool & Machining
 - 8.5.1 Andrew Tool & Machining Details
 - 8.5.2 Andrew Tool & Machining Major Business
 - 8.5.3 Andrew Tool & Machining Aerospace Testing Solutions Product and Services
 - 8.5.4 Andrew Tool & Machining Aerospace Testing Solutions Revenue, Gross Margin and Market Share (2021-2026)
 - 8.5.5 Andrew Tool & Machining Recent Developments/Updates
 - 8.5.6 Andrew Tool & Machining Competitive Strengths & Weaknesses
- 8.6 Eurofins (EAG Laboratories)
 - 8.6.1 Eurofins (EAG Laboratories) Details
 - 8.6.2 Eurofins (EAG Laboratories) Major Business
 - 8.6.3 Eurofins (EAG Laboratories) Aerospace Testing Solutions Product and Services
 - 8.6.4 Eurofins (EAG Laboratories) Aerospace Testing Solutions Revenue, Gross Margin and Market Share (2021-2026)
 - 8.6.5 Eurofins (EAG Laboratories) Recent Developments/Updates
 - 8.6.6 Eurofins (EAG Laboratories) Competitive Strengths & Weaknesses
- 8.7 SGS
 - 8.7.1 SGS Details
 - 8.7.2 SGS Major Business
 - 8.7.3 SGS Aerospace Testing Solutions Product and Services
 - 8.7.4 SGS Aerospace Testing Solutions Revenue, Gross Margin and Market Share (2021-2026)
 - 8.7.5 SGS Recent Developments/Updates
 - 8.7.6 SGS Competitive Strengths & Weaknesses

8.8 Canyon State Inspection

8.8.1 Canyon State Inspection Details

8.8.2 Canyon State Inspection Major Business

8.8.3 Canyon State Inspection Aerospace Testing Solutions Product and Services

8.8.4 Canyon State Inspection Aerospace Testing Solutions Revenue, Gross Margin and Market Share (2021-2026)

8.8.5 Canyon State Inspection Recent Developments/Updates

8.8.6 Canyon State Inspection Competitive Strengths & Weaknesses

8.9 Global Testing Laboratories

8.9.1 Global Testing Laboratories Details

8.9.2 Global Testing Laboratories Major Business

8.9.3 Global Testing Laboratories Aerospace Testing Solutions Product and Services

8.9.4 Global Testing Laboratories Aerospace Testing Solutions Revenue, Gross Margin and Market Share (2021-2026)

8.9.5 Global Testing Laboratories Recent Developments/Updates

8.9.6 Global Testing Laboratories Competitive Strengths & Weaknesses

8.10 Aerospace Testing Services

8.10.1 Aerospace Testing Services Details

8.10.2 Aerospace Testing Services Major Business

8.10.3 Aerospace Testing Services Aerospace Testing Solutions Product and Services

8.10.4 Aerospace Testing Services Aerospace Testing Solutions Revenue, Gross Margin and Market Share (2021-2026)

8.10.5 Aerospace Testing Services Recent Developments/Updates

8.10.6 Aerospace Testing Services Competitive Strengths & Weaknesses

8.11 Aerospace Testing Lab

8.11.1 Aerospace Testing Lab Details

8.11.2 Aerospace Testing Lab Major Business

8.11.3 Aerospace Testing Lab Aerospace Testing Solutions Product and Services

8.11.4 Aerospace Testing Lab Aerospace Testing Solutions Revenue, Gross Margin and Market Share (2021-2026)

8.11.5 Aerospace Testing Lab Recent Developments/Updates

8.11.6 Aerospace Testing Lab Competitive Strengths & Weaknesses

8.12 Collins Aerospace

8.12.1 Collins Aerospace Details

8.12.2 Collins Aerospace Major Business

8.12.3 Collins Aerospace Aerospace Testing Solutions Product and Services

8.12.4 Collins Aerospace Aerospace Testing Solutions Revenue, Gross Margin and Market Share (2021-2026)

8.12.5 Collins Aerospace Recent Developments/Updates

- 8.12.6 Collins Aerospace Competitive Strengths & Weaknesses
- 8.13 Laboratory Testing
 - 8.13.1 Laboratory Testing Details
 - 8.13.2 Laboratory Testing Major Business
 - 8.13.3 Laboratory Testing Aerospace Testing Solutions Product and Services
 - 8.13.4 Laboratory Testing Aerospace Testing Solutions Revenue, Gross Margin and Market Share (2021-2026)
 - 8.13.5 Laboratory Testing Recent Developments/Updates
 - 8.13.6 Laboratory Testing Competitive Strengths & Weaknesses
- 8.14 Innovative Test Solutions (ITS)
 - 8.14.1 Innovative Test Solutions (ITS) Details
 - 8.14.2 Innovative Test Solutions (ITS) Major Business
 - 8.14.3 Innovative Test Solutions (ITS) Aerospace Testing Solutions Product and Services
 - 8.14.4 Innovative Test Solutions (ITS) Aerospace Testing Solutions Revenue, Gross Margin and Market Share (2021-2026)
 - 8.14.5 Innovative Test Solutions (ITS) Recent Developments/Updates
 - 8.14.6 Innovative Test Solutions (ITS) Competitive Strengths & Weaknesses
- 8.15 AeroTEC
 - 8.15.1 AeroTEC Details
 - 8.15.2 AeroTEC Major Business
 - 8.15.3 AeroTEC Aerospace Testing Solutions Product and Services
 - 8.15.4 AeroTEC Aerospace Testing Solutions Revenue, Gross Margin and Market Share (2021-2026)
 - 8.15.5 AeroTEC Recent Developments/Updates
 - 8.15.6 AeroTEC Competitive Strengths & Weaknesses
- 8.16 Intertek
 - 8.16.1 Intertek Details
 - 8.16.2 Intertek Major Business
 - 8.16.3 Intertek Aerospace Testing Solutions Product and Services
 - 8.16.4 Intertek Aerospace Testing Solutions Revenue, Gross Margin and Market Share (2021-2026)
 - 8.16.5 Intertek Recent Developments/Updates
 - 8.16.6 Intertek Competitive Strengths & Weaknesses
- 8.17 VTEC Laboratories
 - 8.17.1 VTEC Laboratories Details
 - 8.17.2 VTEC Laboratories Major Business
 - 8.17.3 VTEC Laboratories Aerospace Testing Solutions Product and Services
 - 8.17.4 VTEC Laboratories Aerospace Testing Solutions Revenue, Gross Margin and

Market Share (2021-2026)

8.17.5 VTEC Laboratories Recent Developments/Updates

8.17.6 VTEC Laboratories Competitive Strengths & Weaknesses

8.18 Quality Liaison Services (QLS)

8.18.1 Quality Liaison Services (QLS) Details

8.18.2 Quality Liaison Services (QLS) Major Business

8.18.3 Quality Liaison Services (QLS) Aerospace Testing Solutions Product and Services

8.18.4 Quality Liaison Services (QLS) Aerospace Testing Solutions Revenue, Gross Margin and Market Share (2021-2026)

8.18.5 Quality Liaison Services (QLS) Recent Developments/Updates

8.18.6 Quality Liaison Services (QLS) Competitive Strengths & Weaknesses

8.19 GE Aerospace

8.19.1 GE Aerospace Details

8.19.2 GE Aerospace Major Business

8.19.3 GE Aerospace Aerospace Testing Solutions Product and Services

8.19.4 GE Aerospace Aerospace Testing Solutions Revenue, Gross Margin and Market Share (2021-2026)

8.19.5 GE Aerospace Recent Developments/Updates

8.19.6 GE Aerospace Competitive Strengths & Weaknesses

8.20 Aeroblaze Laboratory

8.20.1 Aeroblaze Laboratory Details

8.20.2 Aeroblaze Laboratory Major Business

8.20.3 Aeroblaze Laboratory Aerospace Testing Solutions Product and Services

8.20.4 Aeroblaze Laboratory Aerospace Testing Solutions Revenue, Gross Margin and Market Share (2021-2026)

8.20.5 Aeroblaze Laboratory Recent Developments/Updates

8.20.6 Aeroblaze Laboratory Competitive Strengths & Weaknesses

8.21 The Boeing Company

8.21.1 The Boeing Company Details

8.21.2 The Boeing Company Major Business

8.21.3 The Boeing Company Aerospace Testing Solutions Product and Services

8.21.4 The Boeing Company Aerospace Testing Solutions Revenue, Gross Margin and Market Share (2021-2026)

8.21.5 The Boeing Company Recent Developments/Updates

8.21.6 The Boeing Company Competitive Strengths & Weaknesses

8.22 Independent Testing Laboratories

8.22.1 Independent Testing Laboratories Details

8.22.2 Independent Testing Laboratories Major Business

8.22.3 Independent Testing Laboratories Aerospace Testing Solutions Product and Services

8.22.4 Independent Testing Laboratories Aerospace Testing Solutions Revenue, Gross Margin and Market Share (2021-2026)

8.22.5 Independent Testing Laboratories Recent Developments/Updates

8.22.6 Independent Testing Laboratories Competitive Strengths & Weaknesses

8.23 IMR Test Labs

8.23.1 IMR Test Labs Details

8.23.2 IMR Test Labs Major Business

8.23.3 IMR Test Labs Aerospace Testing Solutions Product and Services

8.23.4 IMR Test Labs Aerospace Testing Solutions Revenue, Gross Margin and Market Share (2021-2026)

8.23.5 IMR Test Labs Recent Developments/Updates

8.23.6 IMR Test Labs Competitive Strengths & Weaknesses

8.24 Axiometrix Solutions

8.24.1 Axiometrix Solutions Details

8.24.2 Axiometrix Solutions Major Business

8.24.3 Axiometrix Solutions Aerospace Testing Solutions Product and Services

8.24.4 Axiometrix Solutions Aerospace Testing Solutions Revenue, Gross Margin and Market Share (2021-2026)

8.24.5 Axiometrix Solutions Recent Developments/Updates

8.24.6 Axiometrix Solutions Competitive Strengths & Weaknesses

8.25 Aerospace & Advanced Composites

8.25.1 Aerospace & Advanced Composites Details

8.25.2 Aerospace & Advanced Composites Major Business

8.25.3 Aerospace & Advanced Composites Aerospace Testing Solutions Product and Services

8.25.4 Aerospace & Advanced Composites Aerospace Testing Solutions Revenue, Gross Margin and Market Share (2021-2026)

8.25.5 Aerospace & Advanced Composites Recent Developments/Updates

8.25.6 Aerospace & Advanced Composites Competitive Strengths & Weaknesses

8.26 JMAS

8.26.1 JMAS Details

8.26.2 JMAS Major Business

8.26.3 JMAS Aerospace Testing Solutions Product and Services

8.26.4 JMAS Aerospace Testing Solutions Revenue, Gross Margin and Market Share (2021-2026)

8.26.5 JMAS Recent Developments/Updates

8.26.6 JMAS Competitive Strengths & Weaknesses

9 INDUSTRY CHAIN ANALYSIS

9.1 Aerospace Testing Solutions Industry Chain

9.2 Aerospace Testing Solutions Upstream Analysis

9.3 Aerospace Testing Solutions Midstream Analysis

9.4 Aerospace Testing Solutions Downstream Analysis

10 RESEARCH FINDINGS AND CONCLUSION

11 APPENDIX

11.1 Methodology

11.2 Research Process and Data Source

11.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World GLP-1/GIPR Dual Peptide Agonist Production Value by Region (2021, 2025 and 2032) & (USD Million)

Table 2. World GLP-1/GIPR Dual Peptide Agonist Production Value by Region (2021-2026) & (USD Million)

Table 3. World GLP-1/GIPR Dual Peptide Agonist Production Value by Region (2027-2032) & (USD Million)

Table 4. World GLP-1/GIPR Dual Peptide Agonist Production Value Market Share by Region (2021-2026)

Table 5. World GLP-1/GIPR Dual Peptide Agonist Production Value Market Share by Region (2027-2032)

Table 6. World GLP-1/GIPR Dual Peptide Agonist Production by Region (2021-2026) & (K Units)

Table 7. World GLP-1/GIPR Dual Peptide Agonist Production by Region (2027-2032) & (K Units)

Table 8. World GLP-1/GIPR Dual Peptide Agonist Production Market Share by Region (2021-2026)

Table 9. World GLP-1/GIPR Dual Peptide Agonist Production Market Share by Region (2027-2032)

Table 10. World GLP-1/GIPR Dual Peptide Agonist Average Price by Region (2021-2026) & (US\$/Unit)

Table 11. World GLP-1/GIPR Dual Peptide Agonist Average Price by Region (2027-2032) & (US\$/Unit)

Table 12. GLP-1/GIPR Dual Peptide Agonist Major Market Trends

Table 13. World GLP-1/GIPR Dual Peptide Agonist Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Units)

Table 14. World GLP-1/GIPR Dual Peptide Agonist Consumption by Region (2021-2026) & (K Units)

Table 15. World GLP-1/GIPR Dual Peptide Agonist Consumption Forecast by Region (2027-2032) & (K Units)

Table 16. World GLP-1/GIPR Dual Peptide Agonist Production Value by Manufacturer (2021-2026) & (USD Million)

Table 17. Production Value Market Share of Key GLP-1/GIPR Dual Peptide Agonist Producers in 2025

Table 18. World GLP-1/GIPR Dual Peptide Agonist Production by Manufacturer (2021-2026) & (K Units)

Table 19. Production Market Share of Key GLP-1/GIPR Dual Peptide Agonist Producers in 2025

Table 20. World GLP-1/GIPR Dual Peptide Agonist Average Price by Manufacturer (2021-2026) & (US\$/Unit)

Table 21. Global GLP-1/GIPR Dual Peptide Agonist Company Evaluation Quadrant

Table 22. World GLP-1/GIPR Dual Peptide Agonist Industry Rank of Major Manufacturers, Based on Production Value in 2025

Table 23. Head Office and GLP-1/GIPR Dual Peptide Agonist Production Site of Key Manufacturer

Table 24. GLP-1/GIPR Dual Peptide Agonist Market: Company Product Type Footprint

Table 25. GLP-1/GIPR Dual Peptide Agonist Market: Company Product Application Footprint

Table 26. GLP-1/GIPR Dual Peptide Agonist Competitive Factors

Table 27. GLP-1/GIPR Dual Peptide Agonist New Entrant and Capacity Expansion Plans

Table 28. GLP-1/GIPR Dual Peptide Agonist Mergers & Acquisitions Activity

Table 29. United States VS China GLP-1/GIPR Dual Peptide Agonist Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)

Table 30. United States VS China GLP-1/GIPR Dual Peptide Agonist Production Comparison, (2021 & 2025 & 2032) & (K Units)

Table 31. United States VS China GLP-1/GIPR Dual Peptide Agonist Consumption Comparison, (2021 & 2025 & 2032) & (K Units)

Table 32. United States Based GLP-1/GIPR Dual Peptide Agonist Manufacturers, Headquarters and Production Site (States, Country)

Table 33. United States Based Manufacturers GLP-1/GIPR Dual Peptide Agonist Production Value, (2021-2026) & (USD Million)

Table 34. United States Based Manufacturers GLP-1/GIPR Dual Peptide Agonist Production Value Market Share (2021-2026)

Table 35. United States Based Manufacturers GLP-1/GIPR Dual Peptide Agonist Production (2021-2026) & (K Units)

Table 36. United States Based Manufacturers GLP-1/GIPR Dual Peptide Agonist Production Market Share (2021-2026)

Table 37. China Based GLP-1/GIPR Dual Peptide Agonist Manufacturers, Headquarters and Production Site (Province, Country)

Table 38. China Based Manufacturers GLP-1/GIPR Dual Peptide Agonist Production Value, (2021-2026) & (USD Million)

Table 39. China Based Manufacturers GLP-1/GIPR Dual Peptide Agonist Production Value Market Share (2021-2026)

Table 40. China Based Manufacturers GLP-1/GIPR Dual Peptide Agonist Production,

(2021-2026) & (K Units)

Table 41. China Based Manufacturers GLP-1/GIPR Dual Peptide Agonist Production Market Share (2021-2026)

Table 42. Rest of World Based GLP-1/GIPR Dual Peptide Agonist Manufacturers, Headquarters and Production Site (State, Country)

Table 43. Rest of World Based Manufacturers GLP-1/GIPR Dual Peptide Agonist Production Value, (2021-2026) & (USD Million)

Table 44. Rest of World Based Manufacturers GLP-1/GIPR Dual Peptide Agonist Production Value Market Share (2021-2026)

Table 45. Rest of World Based Manufacturers GLP-1/GIPR Dual Peptide Agonist Production, (2021-2026) & (K Units)

Table 46. Rest of World Based Manufacturers GLP-1/GIPR Dual Peptide Agonist Production Market Share (2021-2026)

Table 47. World GLP-1/GIPR Dual Peptide Agonist Production Value by Type, (USD Million), 2021 & 2025 & 2032

Table 48. World GLP-1/GIPR Dual Peptide Agonist Production by Type (2021-2026) & (K Units)

Table 49. World GLP-1/GIPR Dual Peptide Agonist Production by Type (2027-2032) & (K Units)

Table 50. World GLP-1/GIPR Dual Peptide Agonist Production Value by Type (2021-2026) & (USD Million)

Table 51. World GLP-1/GIPR Dual Peptide Agonist Production Value by Type (2027-2032) & (USD Million)

Table 52. World GLP-1/GIPR Dual Peptide Agonist Average Price by Type (2021-2026) & (US\$/Unit)

Table 53. World GLP-1/GIPR Dual Peptide Agonist Average Price by Type (2027-2032) & (US\$/Unit)

Table 54. World GLP-1/GIPR Dual Peptide Agonist Production Value by Receptor Agonist Properties, (USD Million), 2021 & 2025 & 2032

Table 55. World GLP-1/GIPR Dual Peptide Agonist Production by Receptor Agonist Properties (2021-2026) & (K Units)

Table 56. World GLP-1/GIPR Dual Peptide Agonist Production by Receptor Agonist Properties (2027-2032) & (K Units)

Table 57. World GLP-1/GIPR Dual Peptide Agonist Production Value by Receptor Agonist Properties (2021-2026) & (USD Million)

Table 58. World GLP-1/GIPR Dual Peptide Agonist Production Value by Receptor Agonist Properties (2027-2032) & (USD Million)

Table 59. World GLP-1/GIPR Dual Peptide Agonist Average Price by Receptor Agonist Properties (2021-2026) & (US\$/Unit)

- Table 60. World GLP-1/GIPR Dual Peptide Agonist Average Price by Receptor Agonist Properties (2027-2032) & (US\$/Unit)
- Table 61. World GLP-1/GIPR Dual Peptide Agonist Production Value by Medicinal Efficacy, (USD Million), 2021 & 2025 & 2032
- Table 62. World GLP-1/GIPR Dual Peptide Agonist Production by Medicinal Efficacy (2021-2026) & (K Units)
- Table 63. World GLP-1/GIPR Dual Peptide Agonist Production by Medicinal Efficacy (2027-2032) & (K Units)
- Table 64. World GLP-1/GIPR Dual Peptide Agonist Production Value by Medicinal Efficacy (2021-2026) & (USD Million)
- Table 65. World GLP-1/GIPR Dual Peptide Agonist Production Value by Medicinal Efficacy (2027-2032) & (USD Million)
- Table 66. World GLP-1/GIPR Dual Peptide Agonist Average Price by Medicinal Efficacy (2021-2026) & (US\$/Unit)
- Table 67. World GLP-1/GIPR Dual Peptide Agonist Average Price by Medicinal Efficacy (2027-2032) & (US\$/Unit)
- Table 68. World GLP-1/GIPR Dual Peptide Agonist Production Value by Application, (USD Million), 2021 & 2025 & 2032
- Table 69. World GLP-1/GIPR Dual Peptide Agonist Production by Application (2021-2026) & (K Units)
- Table 70. World GLP-1/GIPR Dual Peptide Agonist Production by Application (2027-2032) & (K Units)
- Table 71. World GLP-1/GIPR Dual Peptide Agonist Production Value by Application (2021-2026) & (USD Million)
- Table 72. World GLP-1/GIPR Dual Peptide Agonist Production Value by Application (2027-2032) & (USD Million)
- Table 73. World GLP-1/GIPR Dual Peptide Agonist Average Price by Application (2021-2026) & (US\$/Unit)
- Table 74. World GLP-1/GIPR Dual Peptide Agonist Average Price by Application (2027-2032) & (US\$/Unit)
- Table 75. Eli Lilly Basic Information, Manufacturing Base and Competitors
- Table 76. Eli Lilly Major Business
- Table 77. Eli Lilly GLP-1/GIPR Dual Peptide Agonist Product and Services
- Table 78. Eli Lilly GLP-1/GIPR Dual Peptide Agonist Production (K Units), Price (US\$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
- Table 79. Eli Lilly Recent Developments/Updates
- Table 80. Eli Lilly Competitive Strengths & Weaknesses
- Table 81. Roche Basic Information, Manufacturing Base and Competitors

Table 82. Roche Major Business

Table 83. Roche GLP-1/GIPR Dual Peptide Agonist Product and Services

Table 84. Roche GLP-1/GIPR Dual Peptide Agonist Production (K Units), Price (US\$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 85. Roche Recent Developments/Updates

Table 86. Roche Competitive Strengths & Weaknesses

Table 87. Viking Therapeutics Basic Information, Manufacturing Base and Competitors

Table 88. Viking Therapeutics Major Business

Table 89. Viking Therapeutics GLP-1/GIPR Dual Peptide Agonist Product and Services

Table 90. Viking Therapeutics GLP-1/GIPR Dual Peptide Agonist Production (K Units), Price (US\$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 91. Viking Therapeutics Recent Developments/Updates

Table 92. Viking Therapeutics Competitive Strengths & Weaknesses

Table 93. Asclepis Pharma Basic Information, Manufacturing Base and Competitors

Table 94. Asclepis Pharma Major Business

Table 95. Asclepis Pharma GLP-1/GIPR Dual Peptide Agonist Product and Services

Table 96. Asclepis Pharma GLP-1/GIPR Dual Peptide Agonist Production (K Units), Price (US\$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 97. Asclepis Pharma Recent Developments/Updates

Table 98. Asclepis Pharma Competitive Strengths & Weaknesses

Table 99. Jiangsu Hengrui Medicine Basic Information, Manufacturing Base and Competitors

Table 100. Jiangsu Hengrui Medicine Major Business

Table 101. Jiangsu Hengrui Medicine GLP-1/GIPR Dual Peptide Agonist Product and Services

Table 102. Jiangsu Hengrui Medicine GLP-1/GIPR Dual Peptide Agonist Production (K Units), Price (US\$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 103. Jiangsu Hengrui Medicine Recent Developments/Updates

Table 104. Jiangsu Hengrui Medicine Competitive Strengths & Weaknesses

Table 105. East China Pharmaceutical Basic Information, Manufacturing Base and Competitors

Table 106. East China Pharmaceutical Major Business

Table 107. East China Pharmaceutical GLP-1/GIPR Dual Peptide Agonist Product and Services

Table 108. East China Pharmaceutical GLP-1/GIPR Dual Peptide Agonist Production (K

Units), Price (US\$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 109. East China Pharmaceutical Recent Developments/Updates

Table 110. East China Pharmaceutical Competitive Strengths & Weaknesses

Table 111. Tonghua Dongbao Pharmaceutical Basic Information, Manufacturing Base and Competitors

Table 112. Tonghua Dongbao Pharmaceutical Major Business

Table 113. Tonghua Dongbao Pharmaceutical GLP-1/GIPR Dual Peptide Agonist Product and Services

Table 114. Tonghua Dongbao Pharmaceutical GLP-1/GIPR Dual Peptide Agonist Production (K Units), Price (US\$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 115. Tonghua Dongbao Pharmaceutical Recent Developments/Updates

Table 116. Tonghua Dongbao Pharmaceutical Competitive Strengths & Weaknesses

Table 117. Lepu Medical Technology Basic Information, Manufacturing Base and Competitors

Table 118. Lepu Medical Technology Major Business

Table 119. Lepu Medical Technology GLP-1/GIPR Dual Peptide Agonist Product and Services

Table 120. Lepu Medical Technology GLP-1/GIPR Dual Peptide Agonist Production (K Units), Price (US\$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 121. Lepu Medical Technology Recent Developments/Updates

Table 122. Lepu Medical Technology Competitive Strengths & Weaknesses

Table 123. Hansoh Pharma Basic Information, Manufacturing Base and Competitors

Table 124. Hansoh Pharma Major Business

Table 125. Hansoh Pharma GLP-1/GIPR Dual Peptide Agonist Product and Services

Table 126. Hansoh Pharma GLP-1/GIPR Dual Peptide Agonist Production (K Units), Price (US\$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)

Table 127. Hansoh Pharma Recent Developments/Updates

Table 128. Hansoh Pharma Competitive Strengths & Weaknesses

Table 129. Global Key Players of GLP-1/GIPR Dual Peptide Agonist Upstream (Raw Materials)

Table 130. Global GLP-1/GIPR Dual Peptide Agonist Typical Customers

Table 131. GLP-1/GIPR Dual Peptide Agonist Typical Distributors

List Of Figures

LIST OF FIGURES

Figure 1. GLP-1/GIPR Dual Peptide Agonist Picture

Figure 2. World GLP-1/GIPR Dual Peptide Agonist Production Value: 2021 & 2025 & 2032, (USD Million)

Figure 3. World GLP-1/GIPR Dual Peptide Agonist Production Value and Forecast (2021-2032) & (USD Million)

Figure 4. World GLP-1/GIPR Dual Peptide Agonist Production (2021-2032) & (K Units)

Figure 5. World GLP-1/GIPR Dual Peptide Agonist Average Price (2021-2032) & (US\$/Unit)

Figure 6. World GLP-1/GIPR Dual Peptide Agonist Production Value Market Share by Region (2021-2032)

Figure 7. World GLP-1/GIPR Dual Peptide Agonist Production Market Share by Region (2021-2032)

Figure 8. North America GLP-1/GIPR Dual Peptide Agonist Production (2021-2032) & (K Units)

Figure 9. Europe GLP-1/GIPR Dual Peptide Agonist Production (2021-2032) & (K Units)

Figure 10. China GLP-1/GIPR Dual Peptide Agonist Production (2021-2032) & (K Units)

Figure 11. Japan GLP-1/GIPR Dual Peptide Agonist Production (2021-2032) & (K Units)

Figure 12. India GLP-1/GIPR Dual Peptide Agonist Production (2021-2032) & (K Units)

Figure 13. GLP-1/GIPR Dual Peptide Agonist Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World GLP-1/GIPR Dual Peptide Agonist Consumption (2021-2032) & (K Units)

Figure 16. World GLP-1/GIPR Dual Peptide Agonist Consumption Market Share by Region (2021-2032)

Figure 17. United States GLP-1/GIPR Dual Peptide Agonist Consumption (2021-2032) & (K Units)

Figure 18. China GLP-1/GIPR Dual Peptide Agonist Consumption (2021-2032) & (K Units)

Figure 19. Europe GLP-1/GIPR Dual Peptide Agonist Consumption (2021-2032) & (K Units)

Figure 20. Japan GLP-1/GIPR Dual Peptide Agonist Consumption (2021-2032) & (K Units)

Figure 21. South Korea GLP-1/GIPR Dual Peptide Agonist Consumption (2021-2032) & (K Units)

Figure 22. ASEAN GLP-1/GIPR Dual Peptide Agonist Consumption (2021-2032) & (K

Units)

Figure 23. India GLP-1/GIPR Dual Peptide Agonist Consumption (2021-2032) & (K Units)

Figure 24. Producer Shipments of GLP-1/GIPR Dual Peptide Agonist by Manufacturer Revenue (\$MM) and Market Share (%): 2025

Figure 25. Global Four-firm Concentration Ratios (CR4) for GLP-1/GIPR Dual Peptide Agonist Markets in 2025

Figure 26. Global Four-firm Concentration Ratios (CR8) for GLP-1/GIPR Dual Peptide Agonist Markets in 2025

Figure 27. United States VS China: GLP-1/GIPR Dual Peptide Agonist Production Value Market Share Comparison (2021 & 2025 & 2032)

Figure 28. United States VS China: GLP-1/GIPR Dual Peptide Agonist Production Market Share Comparison (2021 & 2025 & 2032)

Figure 29. United States VS China: GLP-1/GIPR Dual Peptide Agonist Consumption Market Share Comparison (2021 & 2025 & 2032)

Figure 30. United States Based Manufacturers GLP-1/GIPR Dual Peptide Agonist Production Market Share 2025

Figure 31. China Based Manufacturers GLP-1/GIPR Dual Peptide Agonist Production Market Share 2025

Figure 32. Rest of World Based Manufacturers GLP-1/GIPR Dual Peptide Agonist Production Market Share 2025

Figure 33. World GLP-1/GIPR Dual Peptide Agonist Production Value by Type, (USD Million), 2021 & 2025 & 2032

Figure 34. World GLP-1/GIPR Dual Peptide Agonist Production Value Market Share by Type in 2025

Figure 35. Injection

Figure 36. Oral Administration

Figure 37. World GLP-1/GIPR Dual Peptide Agonist Production Market Share by Type (2021-2032)

Figure 38. World GLP-1/GIPR Dual Peptide Agonist Production Value Market Share by Type (2021-2032)

Figure 39. World GLP-1/GIPR Dual Peptide Agonist Average Price by Type (2021-2032) & (US\$/Unit)

Figure 40. World GLP-1/GIPR Dual Peptide Agonist Production Value by Receptor Agonist Properties, (USD Million), 2021 & 2025 & 2032

Figure 41. World GLP-1/GIPR Dual Peptide Agonist Production Value Market Share by Receptor Agonist Properties in 2025

Figure 42. Balanced

Figure 43. Biased

Figure 44. World GLP-1/GIPR Dual Peptide Agonist Production Market Share by Receptor Agonist Properties (2021-2032)

Figure 45. World GLP-1/GIPR Dual Peptide Agonist Production Value Market Share by Receptor Agonist Properties (2021-2032)

Figure 46. World GLP-1/GIPR Dual Peptide Agonist Average Price by Receptor Agonist Properties (2021-2032) & (US\$/Unit)

Figure 47. World GLP-1/GIPR Dual Peptide Agonist Production Value by Medicinal Efficacy, (USD Million), 2021 & 2025 & 2032

Figure 48. World GLP-1/GIPR Dual Peptide Agonist Production Value Market Share by Medicinal Efficacy in 2025

Figure 49. Long-acting

Figure 50. Short-acting

Figure 51. World GLP-1/GIPR Dual Peptide Agonist Production Market Share by Medicinal Efficacy (2021-2032)

Figure 52. World GLP-1/GIPR Dual Peptide Agonist Production Value Market Share by Medicinal Efficacy (2021-2032)

Figure 53. World GLP-1/GIPR Dual Peptide Agonist Average Price by Medicinal Efficacy (2021-2032) & (US\$/Unit)

Figure 54. World GLP-1/GIPR Dual Peptide Agonist Production Value by Application, (USD Million), 2021 & 2025 & 2032

Figure 55. World GLP-1/GIPR Dual Peptide Agonist Production Value Market Share by Application in 2025

Figure 56. Diabetes

Figure 57. Obesity

Figure 58. Others

Figure 59. World GLP-1/GIPR Dual Peptide Agonist Production Market Share by Application (2021-2032)

Figure 60. World GLP-1/GIPR Dual Peptide Agonist Production Value Market Share by Application (2021-2032)

Figure 61. World GLP-1/GIPR Dual Peptide Agonist Average Price by Application (2021-2032) & (US\$/Unit)

Figure 62. GLP-1/GIPR Dual Peptide Agonist Industry Chain

Figure 63. GLP-1/GIPR Dual Peptide Agonist Procurement Model

Figure 64. GLP-1/GIPR Dual Peptide Agonist Sales Model

Figure 65. GLP-1/GIPR Dual Peptide Agonist Sales Channels, Direct Sales, and Distribution

Figure 66. Methodology

Figure 67. Research Process and Data Source

I would like to order

Product name: Global GLP-1/GIPR Dual Peptide Agonist Supply, Demand and Key Producers, 2026-2032

Product link: <https://marketpublishers.com/r/GE3890F720D6EN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE3890F720D6EN.html>